Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovas... (serin dosed twice daily versus placebo o...)

HOME >> MEDICINE >> TECHNOLOGY

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

Date:6/6/2009

serin dosed twice daily versus placebo over a two-year treatment period in obese patients (Body Mass Index, or BMI, 30 to 45) with or without co-morbid conditions and overweight patients (BMI 27 to less than 30) with at least one co-morbid condition. The trial did not include any dose titration or run-in period. Patients were randomized in a 1:1 ratio to lorcaserin or placebo at baseline. At Week 52, 856 patients taking lorcaserin were re-randomized in a 2:1 ratio to continue lorcaserin or to switch to placebo, and 697 patients on placebo were continued on placebo. Patients received echocardiograms at screening, and at 6, 12, 18 and 24 months after initiating dosing in the trial; patients with FDA-defined valvulopathy were excluded from enrolling in the trial.

Phase 3 Program Overview

The Phase 3 program consists of three trials, BLOOM, BLOSSOM and BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus), and is planned to enroll a total of approximately 7,800 patients. BLOOM and BLOSSOM comprise the Phase 3 pivotal registration program. BLOSSOM has enrolled 4,008 patients and is evaluating 10 mg of lorcaserin dosed once or twice daily versus placebo over a one-year treatment period in obese patients with or without co-morbid conditions and overweight patients with at least one co-morbid condition at about 100 sites in the US. BLOOM-DM is expected to complete enrollment around the end of June and is evaluating 10 mg of lorcaserin dosed once or twice daily versus placebo over a one-year treatment period in obese and overweight patients with type 2 diabetes at about 60 sites in the US. Approximately 600 patients are expected to be enrolled in BLOOM-DM, which is planned as a supplement to the lorcaserin NDA.

A standardized program of moderate diet and exercise guidance is included in the Phase 3 program. The program's hierarchically ordered co-p
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
2. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
3. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
4. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
5. Critical Pharmaceuticals Enter Sustained Release hGH Arena
6. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
9. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
10. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
11. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes

Post Your Comments:

(Date:5/24/2013)... , May 24, 2013 Regulatory and marketplace ... of many organizations, priority list. ... sectors understand a strong Medical Affairs ... clinical development, market education , and regulatory ... a vital bridge between an organization and one ...

(Date:5/24/2013)... , May 24, 2013 BD (Becton, Dickinson and ... technology company, announced today that it will present at the ... Thursday, May 30, 2013, at 10:40 a.m. (ET). ... from the BD corporate website at www.bd.com/investors and ... About BD BD is a ...

(Date:5/24/2013)... , May 24, 2013 /PRNewswire-iReach/ -- Phoenix Houses of ... substance abuse services organization, is hosting its tenth annual ... Hotel on June 6, 2013. More than 300 people ... for the adolescent residential treatment centers, family therapy, and ... individuals whose accomplishments have positive influences on the health and ...

Breaking Medicine Technology:Building Medical Affairs Capabilities to Ensure Organizational Success across Key Operational Areas 2 Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 2 Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 3

[0] Building Medical Affairs Capabilities to Ensure Organizational Success across Key Operational Areas [0] BD to Present at the Deutsche Bank 38th Annual Health Care Conference [0] Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg

... 6, 2011 Pacira Pharmaceuticals, Inc. (Nasdaq: ... today announced that it has entered into agreements ... Commercialization Services, Inc. (ICS) to support the anticipated ... should it be approved by the Food and ...

... 5, 2011 Reportlinker.com announces ... report is available in its ... Aesthetics (Botox, Dermal Fillers, Collagen) ... Landscape and Market Forecasts to ...

Pacira Pharmaceuticals, Inc. Expands EXPAREL™ Commercial Team Infrastructure Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017

(Date:5/24/2013)... (LA JOLLA, Calif.) (PRWEB) May 24, 2013 ... letter to House Appropriators and the California congressional ... them to restore sequestered industry user fees paid ... 2013, and to ensure that future across-the-board cuts ... as part of the FY14 Agriculture, Rural Development ...

(Date:5/24/2013)... OR (PRWEB) May 24, 2013 ... Sustainable Cards, major competitors in sustainable card material, ... of using forest materials as a sustainable gift ... is to identify industry challenges and increase education ... card programs to support the reduction of carbon ...

(Date:5/24/2013)... May 24 (HealthDay News) -- Drugs commonly used to ... effects that can interfere with vision, according to a ... (PGAs), which are used to reduce eye pressure, have ... changes in eye color, the researchers said, suggesting that ... PGAs. Doctors should be conservative when prescribing ...

(Date:5/24/2013)... 2013 Started in 1982, AMTC’s SHINE event ... 2013 marks AMTC’s 31st anniversary. SHINE is a ministry run ... Millie Lewis and her daughter, Carey Lewis Arban. , This ... directors, and music professionals including the New York Film Academy, ... They are kings of Hollywood and Christian casting directors. They ...

(Date:5/24/2013)... 24, 2013 Let’s face it: very few ... uncommon for the majority of people to be uncomfortable with ... to a coffee addiction or simply genetics, yellowish or stained ... so popular. , Herald Square Dental is proud ... whitening system: Venus White Max. , Teeth become discolored ...

Breaking Medicine News(10 mins):Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 2 Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 3 Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2 Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3 Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2 Health News:AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013 2 Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2

[0] California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 [0] Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants [0] Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds [0] AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013 [0] Herald Square Dental Introduces New In-office Whitening System: Venus White Max

... of Hollywood actress Katie Holmes, has declared that she will ... ,The 18-year-old fashion student, who has infuriated Katie, ... days 15 hours 12 minutes and 40 seconds. ... porn star. Katie is well known as she has fathered ...

... It seems that Hollywood hunk Brad Pitt is enjoying parental bliss ... the pregnant Myleene Klass at Cannes, Pitt poured his heart out ... have had your first scan yet? They're mind-blowing. Get ready to ... - it's the best thing that ever happened to me,' the ...

... majority of chemotherapy errors identified in children reach patients, ... cancer drug errors in children . Published in the ... of the American Cancer Society, the study concluded that ... associated with errors, and that errors in drug administration ...

... scare over soft drinks is in the making following revelations that ... Pepsi Max has the ability to switch off vital parts ... when parts of DNA are disabled, as it were, it could ... as Parkinson's. ,Concerns centre on the safety of E211, ...

... 2007 graduates of the Yale School of Forestry & Environmental ... or develop renewable energy in order to offset the pollution ... on Memorial Day. ,The 131-member class will spend ... carbon dioxide, which is equivalent to the combined weight of ...

... one of the largest ever Parkinson's disease (PD) clinical ... can slow the symptom progression of this disorder. ... in which patients develop tremor, slowness of movements and ... people in the U.S. Currently, there are a number ...

Cached Medicine News:Health News:Most Pediatric Chemotherapy Mistakes Reach Patients 2 Health News:Soft Drink Additive Could Cause Cell Damage 2 Health News:Soft Drink Additive Could Cause Cell Damage 3 Health News:Yale F&ES Graduation to Offset Gas Linked to Global Warming 2 Health News:Emory Participates in Study to Slow Progression of Parkinson's Disease 2

'Katee Holmes' Vs 'Katie Holmes' Case of Losing Virginity Brad Pitt 'loves Being a Dad'Most Pediatric Chemotherapy Mistakes Reach Patients Soft Drink Additive Could Cause Cell Damage Yale F&ES Graduation to Offset Gas Linked to Global Warming Emory Participates in Study to Slow Progression of Parkinson's Disease

... The Trans-Blot SD semi-dry ... and economical blotting. Using a ... anode and a stainless steel ... Trans-Blot SD cell transfers in ...

Semi-Dry Blotting Unit for 10 x 10cm Gels...

... Transfers depurinated DNA and RNA from ... little as 15 minutes ,Increases speed and ... to be applied to gel ,Part of ... transfer and UV crosslinking in 2.5 hours, ...

... from agarose gels to hybridization membranes in ... and efficiency of transfer by allowing high ... of an integrated system allowing electrophoresis, gel ... hours, versus 29 hours required for conventional ...

Medicine Products:

Trans-Blot SD DNA/RNA Blotting Kit Semi-Dry Blotting Units PosiBlot 30-30 Pressure Blotter and Pressure Control Station - 120V PosiBlot 30-30 Pressure Blotter and Pressure Control Station - 230V